drugset / Trial / NCT05662956
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
NaSingle-groupOpen-labelTreatment
Summary
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine and CAG(VA-CAG) as induction regimen in newly diagnosed young patients with acute myeloid leukemia(AML).
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-12-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aclacinomycin | Unknown | 12 mg/m2 | — |
| Subject | Aclacinomycin | Unknown | 14 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 3000 mg/m2 | Subcutaneous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |